Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ADXN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.27% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.62M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.99 | 52 Weeks Range 6.51 - 13.27 | Updated Date 06/30/2025 |
52 Weeks Range 6.51 - 13.27 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-19 | When - | Estimate - | Actual -1.9991 |
Profitability
Profit Margin 3521.74% | Operating Margin (TTM) -853.23% |
Management Effectiveness
Return on Assets (TTM) -25.09% | Return on Equity (TTM) -163.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6091981 | Price to Sales(TTM) 39.09 |
Enterprise Value 6091981 | Price to Sales(TTM) 39.09 | ||
Enterprise Value to Revenue 28.6 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 1069140 | Shares Floating 26107116 |
Shares Outstanding 1069140 | Shares Floating 26107116 | ||
Percent Insiders - | Percent Institutions 1.23 |
Analyst Ratings
Rating 1 | Target Price 30 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd is a pharmaceutical company pioneering allosteric modulation-based drug discovery and development. Founded in 2002, Addex has focused on creating novel therapies for neurological disorders and other diseases by selectively modulating G protein-coupled receptors (GPCRs).
Core Business Areas
- Allosteric Modulator Discovery: Addex specializes in discovering and developing allosteric modulators, small molecules that modulate the activity of GPCRs without directly binding to the active site.
- Drug Development: The company develops drug candidates based on its allosteric modulator platform, advancing them through preclinical and clinical stages.
- Partnerships and Licensing: Addex collaborates with other pharmaceutical companies and licenses its technology and drug candidates.
Leadership and Structure
Addex Therapeutics Ltd is led by a management team with experience in pharmaceutical research and development. The company operates with a structure that focuses on drug discovery, preclinical and clinical development, and business development.
Top Products and Market Share
Key Offerings
- Dipraglurant: Dipraglurant is a negative allosteric modulator (NAM) of mGluR5. It was previously under development for Parkinsonu2019s disease levodopa-induced dyskinesia (PD-LID) and other neurological disorders. Addex is exploring partnering opportunities for this asset. Competitors in the PD-LID space include companies developing therapies targeting dopamine regulation and non-dopaminergic pathways. Market share data specific to Dipraglurant is not publicly available due to its development stage.
- ADX71441: ADX71441 is a positive allosteric modulator (PAM) of mGluR2. The company is exploring partnering opportunities for this asset. Competitors in the mGluR2 modulation space include companies developing therapies for schizophrenia and anxiety disorders. Market share data specific to ADX71441 is not publicly available due to its development stage.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. There is a growing emphasis on precision medicine and targeted therapies.
Positioning
Addex Therapeutics Ltd is positioned as an innovator in allosteric modulation, offering a unique approach to drug discovery. Its competitive advantage lies in its proprietary technology platform and expertise in GPCR modulation.
Total Addressable Market (TAM)
The TAM for neurological disorders and other diseases targeted by Addex's pipeline is substantial, potentially reaching hundreds of billions of dollars globally. Addex's positioning within this TAM depends on the success of its clinical trials and partnering efforts.
Upturn SWOT Analysis
Strengths
- Proprietary allosteric modulator platform
- Expertise in GPCR modulation
- Experienced management team
- Potential for first-in-class therapies
Weaknesses
- Limited financial resources
- Dependence on partnerships for funding
- Clinical trial risk
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Positive clinical trial results
- Increasing demand for targeted therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- NVS
Competitive Landscape
Addex faces competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its innovative allosteric modulation technology. Addex's small market share reflects the difference in resources and approved drugs between Addex and larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be based on past financial performance and pipeline progress.
Future Projections: Future projections would be based on analyst estimates and company guidance.
Recent Initiatives: Recent strategic initiatives include focusing on partnering opportunities for existing assets and exploring new therapeutic areas.
Summary
Addex Therapeutics Ltd is a small cap biotech company with a unique allosteric modulator platform and expertise in GPCR modulation. The company faces challenges due to limited resources and clinical trial risks. Its potential lies in securing partnerships, advancing its pipeline, and capitalizing on the growing demand for targeted therapies. Addex's long term sucess is dependent on the partnering of their assets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.